POLISCOPE
Back to feed
NewsBreitbartMay 2, 2026United States

Trump Administration Initiates Trade Investigation into European Drug Pricing

The Trump administration has launched a Section 301 investigation into European Union countries, specifically targeting Germany, over pharmaceutical pricing policies. The administration argues that European price controls force American taxpayers to subsidize global drug costs and has threatened a 25% tariff increase if these policies are not adjusted.

international tradepharmaceuticalsforeign policytariffshealthcare policy
Read the full story at Breitbart

Why It Matters

This investigation could lead to a 25% on European goods if the U.S. government determines that European drug pricing mandates unfairly burden American consumers and pharmaceutical companies.

Key Facts

  • The Trump administration has launched a Section 301 investigation into European countries regarding pharmaceutical pricing.
  • The administration has threatened to impose a 25% tariff on European Union goods if pricing policies are not changed.
  • The U.S. government alleges that European price controls force American taxpayers to pay higher costs for new drugs.
  • The United Kingdom has reportedly signed an agreement to increase the net price of new drugs in exchange for tariff relief.
  • Germany is specifically identified as a primary target for the investigation due to its mandatory price cuts on imported medicines.
  • The U.S. claims that the U.S. provides approximately two-thirds of new global drug research.

Who's Mentioned

locationGermany“Primary target of the investigation”locationUnited Kingdom“Reported to have signed a drug pricing agreement with the U.S.”personUrsula von der Leyen“European Union Commissioner”personDonald Trump“President of the United States”organizationAmericans for Limited Government“Sponsor of the content”dollar_amount301“Refers to Section 301 of the Trade Act of 1974”